KPV

KPV (Lys-Pro-Val) is a tripeptide fragment of alpha-melanocyte stimulating hormone (α-MSH). Despite being only three amino acids, it retains potent anti-inflammatory and antimicrobial properties of the parent hormone.

KPV is the tiny three-letter peptide everyone in gut-health and skin-inflammation research talks about. It is short, stable, and quietly powerful — the calm-it-down peptide of the inflammation world.

Enters cells and acts intracellularly to inhibit NF-κB signaling and downstream pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). It also exhibits direct antimicrobial activity against multiple bacterial and fungal strains. Its small size supports oral bioavailability for gut-focused research.

Anti-inflammatory tripeptide derived from alpha-MSH. Calms systemic flare-ups, stabilizes intestinal barrier.

1. KPV
2. Local growth-factor and angiogenic signalling
3. Cell migration, matrix remodelling and inflammatory modulation
4. Connective-tissue, gut-lining and wound-repair endpoints

A plain-English read on how much published evidence currently exists for KPV. These ratings describe the volume and maturity of the literature — not effectiveness, safety, or suitability for any use.

Current limitations: most compounds in this category are studied in preclinical or small-sample settings. Absence of large controlled human trials is the single biggest limitation to keep in mind when reading any summary of KPV.

Lyophilized compounds are supplied as a dry powder. Concentration is simply the total amount in the vial divided by the volume of bacteriostatic water added:

Concentration (mg/mL) = total mg in vial ÷ mL of diluent added

Commonly supplied vial sizes

5mg or 10mg vial

Worked concentration example

5mg + 2mL BAC water → 2.5mg/mL On U-100 insulin syringe:

• • 10 units = 250mcg
• • 20 units = 500mcg

Run your own numbers with the reconstitution calculator — it converts vial size and diluent volume into mg/mL and mcg/mL.

The figures below are reported here descriptively, because they are the values most frequently cited in publicly available research literature and reference material. They are not instructions, not a protocol, and not a recommendation. These compounds are supplied for laboratory research use only and are not approved by the FDA for human consumption.

Commonly cited amounts

250–500mcg daily subcutaneous (or oral capsules for gut-specific)

Commonly cited frequency

Daily

Commonly cited study duration

4–6 weeks

Peptides are supplied freeze-dried because peptide bonds degrade far faster in solution than in a dry state. Understanding storage is part of understanding why the powder form exists at all.

• •Lyophilized powder: stored refrigerated, typically stable for months to years.
• •Reconstituted solution: refrigerated at 2–8°C, generally discussed as stable for roughly 30–60 days.
• •Heat and direct light accelerate degradation — vials are kept cool and dark.
• •Reconstituted material is not re-frozen; ice crystal formation disrupts peptide structure.
• •Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which is what allows multi-day storage after reconstitution.

More detail in the storage & handling guide and how peptide quality is evaluated.

• •Inflammatory bowel disease (IBD) models
• •Topical inflammation and wound healing
• •Antimicrobial activity studies
• •Gut barrier integrity research
• •Comparison with BPC-157 and LL-37

A growing favorite in gut-health, IBD-research, and biohacker communities. Common discussion: oral capsules for gut research, topical formulations for skin, and how it compares to BPC-157 for inflammation endpoints.

“Three-letter calm-down for inflamed tissue.”

Often stacked with BPC-157 for gut research, with LL-37 for antimicrobial conversations, and with Thymosin Alpha-1 for broader immune modulation.

KPV is the C-terminal tripeptide fragment of α-MSH, studied for intracellular NF-κB suppression, antimicrobial activity, and gut/skin inflammation research.